Oppenheimer Reiterates Outperform (N/A) on Arqule (ARQL)
Shares of Arqule traded down 0.18% during mid-day trading on Monday, hitting $5.67. Arqule has a one year low of $3.98 and a one year high of $8.32. The company’s market cap is $352.7 million.
Arqule last issued its quarterly earnings data on Thursday, May 3rd. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01. The company’s quarterly revenue was down 36.6% on a year-over-year basis. On average, analysts predict that Arqule will post $-0.08 earnings per share next quarter.
Separately, analysts at Stifel Nicolaus initiated coverage on shares of Arqule in a research note to investors on Thursday, March 15th. They set a “buy” rating and a $13.00 price target on the stock.
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics.